Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials)".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL, in both single-dose and multiple-dose vial formats. Triamcinolone Acetonide is a corticosteroid injectable used to treat various inflammatory and allergic conditions. With this approval, Alembic can now commercially launch and market this generic product in the United States. The approval covers two packaging formats, which broadens the addressable market across different healthcare settings.
This is a positive development as it strengthens Alembic's US injectable portfolio and opens up a new revenue stream from the US generics market. Short-term stock reaction is likely to be mildly positive, with meaningful contribution depending on the size of the addressable market and existing competition.